BioVie Advances Parkinson’s, Long COVID, and Liver Disease Programs Ahead of 2026

BioVie is advancing its drug candidates Bezisterim and BIV201 for Parkinson's disease, long COVID, and liver disease. Bezisterim has shown promising results in prior studies, and BioVie is launching a new clinical trial for earlier-stage Parkinson's disease. The company is also conducting a larger trial for long COVID and has received FDA authorization to advance BIV201 directly into a Phase 3 clinical trial. BioVie expects 2026 to be a transformational year with multiple clinical data readouts and the potential initiation of a pivotal Phase 3 study.